Clinical trial

OBSERVATIONAL STUDY TO ASSESS THE EFFECTIVENESS OF THE INTERVENTION OF THE LOW-SODIUM DIET THROUGH THE MONITORING OF SODIUM IN URINE IN PATIENTS WITH HIGH BLOOD PRESSURE IN THE PRIMARY CARE SETTING

Name

IDI-HTA-2020-01

Description

Arterial hypertension is an independent vascular risk factor and a frequent reason for consultation in Primary Care. It generates high cardiovascular morbidity and mortality (stroke, heart disease, kidney failure and other diseases). Moreover, given that it is a modifiable factor and that there are intervention and control measures that would lead to a significant reduction in cardiovascular incidence and morbimortality, it can be stated that ETS is a major public health problem. The approach to this risk factor can be pharmacological and non-pharmacological. The non-pharmacological approach is based on lifestyle modification. Among the measures aimed at modifying lifestyles is the restriction of daily intake of sodium in the diet. Such restriction enhances the hypotensive effect of pharmacological treatment so that its application and intensification would delay the start of pharmacological therapy, as well as avoid the need to increase the dose of antihypertensive drugs or the number of drugs to be used for the control of hypertension. In relation to salt intake in the Spanish population, the average is above the figures of less than 5 grams per day recommended by the WHO. Sodium intake can be estimated by determining the 24-hour urine sodium concentration. In addition, there is a positive correlation between systolic and diastolic blood pressure figures and the excretion of sodium in urine.

Trial arms

Trial start

2020-09-01

Estimated PCD

2022-09-01

Trial end

2022-09-01

Status

Terminated

Treatment

Adult patients diagnosed and treated for high blood pressure

Educational program interventions conducted by primary care staff to encourage adherence to a low-sodium diet consisting of direct action on the patient and provision of educational materials will be assessed. Compliance and follow-up of the low sodium diet will be done by monitoring the sodium in urine in the target population, selected according to the selection criteria described in the protocol.

Size

Primary endpoint

Systolic and diastolic TA values, the upper limit being 140 (systolic) and the lower range 90 (diastolic).

basal

Systolic and diastolic TA values, the upper limit being 140 (systolic) and the lower range 90 (diastolic).

6 months

Eligibility criteria

Inclusion Criteria: * Patients over 40 years old. * Patients diagnosed with HTA (according to criteria ESC/ESH 2018) in a PA consultation or through MAP at the health center. * In treatment with single, double or triple antihypertensive therapy. * Patients with ST figures ≥140. * Patients with TD numbers ≥90. * Patients with stable antihypertensive treatment or without modifications in the treatment at least in the last month. * Patients who commit to follow up the study. * Patients who have given written informed consent. Exclusion Criteria: * Patients with decompensated heart failure * Severe renal failure. * Decompensated liver disease. * Taking non-insulin antidiabetic * Hypertension of pharmacological origin and other causes.

Protocol

{'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'CASE_ONLY', 'timePerspective': 'PROSPECTIVE'}, 'enrollmentInfo': {'count': 2, 'type': 'ACTUAL'}}

Updated at

2023-03-02

1 organization

1 product

4 indications

Organization

Instituto de Investigación Marqués de Valdecilla

Product

Indication

Indication

Indication

Indication